share_log

HC Wainwright & Co. Reiterates Buy on Lineage Cell Therapeutics, Maintains $7 Price Target

Benzinga ·  Apr 26, 2023 06:15

HC Wainwright & Co. analyst Joseph Pantginis reiterates Lineage Cell Therapeutics (AMEX:LCTX) with a Buy and maintains $7 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment